CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and effo ...

Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for '25 On-Demand Conference, where CEO John Climaco ou ...

BACKGROUND: Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells.

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

On-demand video webcast now available here HOUSTON, TX / ACCESSWIRE / 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a bi ...

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...